Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM.

J Immunother Cancer. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x.

2.

Melanoma vaccines: clinical status and immune endpoints.

Maurer DM, Butterfield LH, Vujanovic L.

Melanoma Res. 2019 Apr;29(2):109-118. doi: 10.1097/CMR.0000000000000535.

PMID:
30802228
3.

CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α.

Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A, Huang A, Kirkwood JM, Butterfield LH.

Front Immunol. 2019 Jan 29;10:14. doi: 10.3389/fimmu.2019.00014. eCollection 2019.

4.

ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.

Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL.

J Cancer. 2018 Jun 23;9(14):2559-2570. doi: 10.7150/jca.24601. eCollection 2018.

5.

Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death.

Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH.

Cancer Immunol Res. 2017 Jun;5(6):493-502. doi: 10.1158/2326-6066.CIR-16-0216. Epub 2017 May 3.

6.

Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice.

Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL.

Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. Epub 2016 Feb 19.

7.

Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma.

Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP, Vujanovic L, Mizejewski GJ, Watkins SC, Butterfield LH.

J Immunother Cancer. 2015 Jul 21;3:32. doi: 10.1186/s40425-015-0077-x. eCollection 2015.

8.

Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses.

Vujanovic L, Shi J, Kirkwood JM, Storkus WJ, Butterfield LH.

Oncoimmunology. 2014 Nov 14;3(8):e954501. eCollection 2014.

9.

Drug-related pityriasis rubra pilaris with acantholysis.

Gajinov ZT, Matić MB, Duran VD, Vucković N, Prcić ST, Vujanović LM.

Vojnosanit Pregl. 2013 Sep;70(9):871-3.

PMID:
24266317
10.

Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.

Naveh HP, Vujanovic L, Butterfield LH.

J Immunother Cancer. 2013 Nov 18;1:19. doi: 10.1186/2051-1426-1-19. eCollection 2013.

11.

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.

Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH.

Oncoimmunology. 2012 Jul 1;1(4):448-457.

12.

Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH.

Oncoimmunology. 2012 May 1;1(3):287-357.

13.

Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer.

Baskic D, Vujanovic L, Arsenijevic N, Whiteside TL, Myers EN, Vujanovic NL.

Head Neck. 2013 Mar;35(3):388-98. doi: 10.1002/hed.22968. Epub 2012 Apr 5.

14.

Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.

Bray SM, Vujanovic L, Butterfield LH.

Clin Dev Immunol. 2011;2011:249281. doi: 10.1155/2011/249281. Epub 2011 Sep 28.

15.

New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Butterfield LH, Vujanovic L.

Curr Opin Investig Drugs. 2010 Dec;11(12):1399-408. Review.

16.

Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH.

Blood. 2010 Jul 29;116(4):575-83. doi: 10.1182/blood-2009-08-240325. Epub 2010 Apr 29.

17.

Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer.

Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, Szczepanski MJ, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, Myers EN, Vujanovic NL.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2913-22. doi: 10.1158/1055-9965.EPI-08-0898. Epub 2009 Oct 20.

18.

Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH.

Cancer Immunol Immunother. 2009 Jan;58(1):121-33. doi: 10.1007/s00262-008-0533-2. Epub 2008 May 17.

19.

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A.

J Immunother. 2008 Apr;31(3):294-309. doi: 10.1097/CJI.0b013e31816a8910.

20.

A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

Vujanovic L, Mandic M, Olson WC, Kirkwood JM, Storkus WJ.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6796-806.

21.

Melanoma cancer vaccines and anti-tumor T cell responses.

Vujanovic L, Butterfield LH.

J Cell Biochem. 2007 Oct 1;102(2):301-10. Review.

PMID:
17647270
22.

[Lupus vulgaris: isolation of Mycobacterium tuberculosis from the affected skin scraping and mucous membranes].

Jovanović M, Sente R, Golusin Z, Kurucin T, Vujanović L, Poljacki M.

Med Pregl. 2006 Nov-Dec;59(11-12):580-3. Serbian.

PMID:
17633902
23.
24.

Acute febrile neutrophilic dermatosis (Sweet's syndrome) after influenza vaccination.

Jovanović M, Poljacki M, Vujanović L, Duran V.

J Am Acad Dermatol. 2005 Feb;52(2):367-9. Review. No abstract available.

PMID:
15692491
25.

Contact allergy to Compositae plants in patients with atopic dermatitis.

Jovanović M, Poljacki M, Duran V, Vujanović L, Sente R, Stojanović S.

Med Pregl. 2004 May-Jun;57(5-6):209-18. English, Serbian.

PMID:
15503788
26.

Sesquiterpene lactone mix patch testing supplemented with dandelion extract in patients with allergic contact dermatitis, atopic dermatitis and non-allergic chronic inflammatory skin diseases.

Jovanović M, Poljacki M, Mimica-Dukić N, Boza P, Vujanović Lj, Duran V, Stojanović S.

Contact Dermatitis. 2004 Sep;51(3):101-10.

PMID:
15479198

Supplemental Content

Loading ...
Support Center